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ABSTRACT
The majority of patients develop resistance against suppression of HER2-signaling 
mediated by trastuzumab in HER2 positive breast cancer (BC). HER2 overexpression 
activates multiple signaling pathways, including the mitogen-activated protein kinase 
(MAPK) cascade. MAPK phosphatases (MKPs) are essential regulators of MAPKs and 
participate in many facets of cellular regulation, including proliferation and apoptosis. 
We aimed to identify whether differential MKPs are associated with resistance to 
targeted therapy in patients previously treated with trastuzumab. Using gene chip data 
of 88 HER2-positive, trastuzumab treated BC patients, candidate MKPs were identified 
by Receiver Operator Characteristics analysis performed in R. Genes were ranked 
using their achieved area under the curve (AUC) values and were further restricted 
to markers significantly associated with worse survival. Functional significance of the 
two strongest predictive markers was evaluated in vitro by gene silencing in HER2 
overexpressing, trastuzumab resistant BC cell lines SKTR and JIMT-1. The strongest 
predictive MKPs were DUSP4/MKP-2 (AUC=0.75, p=0.0096) and DUSP6/MKP-3 
(AUC=0.77, p=5.29E-05). Higher expression for these correlated to worse survival 
(DUSP4: HR=2.05, p=0.009 and DUSP6: HR=2, p=0.0015). Silencing of DUSP4 had 
significant sensitization effects – viability of DUSP4 siRNA transfected, trastuzumab 
treated cells decreased significantly compared to scramble-siRNA transfected controls 
(SKTR: p=0.016; JIMT-1: p=0.016). In contrast, simultaneous treatment with DUSP6 
siRNA and trastuzumab did not alter cell proliferation. Our findings suggest that 
DUSP4 may represent a new potential target to overcome trastuzumab resistance.
INTRODUCTION
Human epidermal growth factor receptor 2 (HER2) 
is a critical member of the epidermal growth factor 
receptor (EGFR) transmembrane receptor tyrosine 
kinase (RTK) family. HER2 does not possess a known 
ligand, but its dimerization domain is in continuous open 
conformation making it the preferred dimerization partner 
of other EGFR RTKs. The hetero- or homodimerization 
induces activation of the PI3K/Akt, Ras/MAPK, and JAK/
STAT pathways, leading to increased cell proliferation 
and survival [1]. Targets of the receptor also modulate 
angiogenesis via activation of VEGFA, suppress apoptosis 
via NFKB and control the cell cycle via p27, cyclin D1 
and D2 [2].
Breast cancer is the leading cause of cancer related 
deaths in the age group of 45-55 year old women. HER2 
is overexpressed in 20-25% of invasive breast cancer [3], 
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that translates to over 46 thousand new HER2-positive 
cases each year in the USA alone [4]. HER2-positivity 
confers aggressive tumor growth, high incidence of 
local recurrence, variable response to conventional 
chemotherapy and worse prognosis in general [5–7]. 
The introduction of the anti-HER2 monoclonal antibody 
trastuzumab in 1998 transformed the course of disease 
for these patients, and today HER2-positivity confers 
better prognosis compared to receptor negativity [8]. 
Trastuzumab is a humanized monoclonal antibody (mAb) 
that attaches to the fourth extracellular domain of the 
HER2 receptor suppressing HER2 signaling. Trastuzumab 
improves objective response rate (ORR), progression free 
survival (PFS) and overall survival (OS) of HER2-positive 
patients [9]. It also provides advantage for disease-free 
survival (DFS) and OS as adjuvant therapy combined 
with chemotherapy [10, 11], or as monotherapy after 
chemotherapy [12]. Recently, excellent prognosis was 
reported in patients with small, stage I, node negative 
tumor after trastuzumab treatment combined with 
paclitaxel [13]. Neoadjuvant trastuzumab combined with 
chemotherapy improved pathologic complete remission 
(pCR) in phase II and III clinical trials [14].
Anti-HER2 therapy is a targeted therapy as 
response can be expected in HER2-positive patients 
only – however, ORR in patients with metastatic disease 
is not more than 50% [15]. In addition, 70% of HER2 
positive patients demonstrate intrinsic or secondary 
resistance to trastuzumab [16]. The major resistance 
mechanisms include: a. impaired access to the binding 
site; b. augmented signaling through other ERBB family 
receptors and their ligands; c. activation of HER2 targets 
by alternative heterodimers and initiation of collateral 
signal transduction; d. signaling triggered by downstream 
pathway members, such as activating mutations in 
PIK3CA or loss of tumor suppressor PTEN; e. altered 
expression of cell cycle and apoptotic regulators; and f. 
hormone receptor status (for a recent review of resistance 
mechanisms see [17]). Most of the numerous biomarkers 
of resistance proposed in pre-clinical studies delivered 
heterogeneous results when evaluated in clinical trials 
[18, 19]. The extent of HER2 amplification and protein 
overexpression predicts response to trastuzumab, and 
remains currently the single marker utilized for patient 
selection [18]. To improve response rate, it will be 
imperative to identify additional biomarkers capable of 
further differentiating patients regarding their resistance 
to anti-HER2 treatment.
HER2 overexpression activates multiple signaling 
pathways, including the mitogen-activated protein kinase 
(MAPK) cascade. MAPKs, such as ERK, JNK and 
p38 drive many facets of cellular regulation, including 
proliferation and differentiation [20]. Constitutive 
activation of MAPKs has been associated with cancer 
development [21]. Tumor relevant MAPKs are regulated 
by mitogen-activated protein kinase phosphatases (MKPs), 
a subgroup of dual-specificity phosphatases (DUSPs). 
The ten members of the MKP family are subdivided into 
three groups based on cellular localization and substrate 
specificity, and exert complex spatial and temporal control 
on MAPK signaling [22]. Both up- and down-regulation of 
MKPs were linked to the development of various human 
cancers [23]. The role of MKPs is highly tissue specific 
and also depends on the mutations present in malignant 
transformations [24]. Dysregulation of MKPs, such as 
DUSP1/MKP-1, mediates chemoresistance in cancer cells 
[25–27].
While tyrosine kinases received much attention in 
HER2 driven tumorigenesis, the role of MPKs remains 
mostly unexplored. The failure of trastuzumab to suppress 
HER2-mediated signaling suggest placing regulators 
of proliferation and apoptosis, such as MKPs, under 
close scrutiny. Here we hypothesized that differential 
expression of MKPs is associated with therapy resistance 
in previously trastuzumab treated patients. In our study 
candidate MKPs were identified using two independent 
transcriptomic cohorts, and were restricted to markers 
associated with survival benefit in HER2-positive patients. 
The strongest predictive biomarkers, DUSP4/MKP-2 and 
DUSP6/MKP-3 were evaluated in vitro, in which their 
functional role was investigated in trastuzumab resistant 
cell lines.
RESULTS
Identification of biomarker-candidates in 
trastuzumab-treated breast cancer cohorts
All the HER2 positive patients included in 
the statistical analysis received trastuzumab and 
chemotherapy. In the statistical analysis, only 
samples for which response data were available were 
included. Aggregate clinical, pathological and survival 
characteristics for the included datasets are presented in 
Table 1.
We performed ROC analysis for all MKP genes 
independently on both platforms. Based on AUC values 
DUSP4 and DUSP6 were the best performing MKPs 
(average AUC=0.687 for DUSP4 and 0.728 for DUSP6). 
DUSP1 (AUC=0.678) and DUSP16 (AUC=0.7667) 
reached significance only in one platform of the two, 
therefore were excluded from further analysis. The 
complete list of all significant AUC values from the two 
platforms for each MKPs are presented in Table 2.
Survival analysis
Survival analysis was drawn from the survival data 
of 252 HER2 positive patients. All of the patients were 
HER2 positive (cut off 4800), 65.8% ER positive (cut off 
500) both defined by the gene expression. The patients’ 
clinical characteristics (from the available data) were 
the following: 51.1 years median age, 2.3 cm average 
tumor size, 4.7 months median relapse free time, 6.6 
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Table 1: Comparison of the microarray datasets used to assess the association of gene to response against anti-HER2 
therapy
Dataset Affymetrix dataset Agilent dataset [57]
n 50 11 27
Platform GPL96 GPL1708 GPL5325
Clinical characteristics
- Mean age (years) 49.42 47.43 n.a.
- Lymph node positive (%) 15 (29.4%) n.a. n.a.
- ER status (negative %) 64% 55% 56%
- PR status (negative %) 74% 64% 70%
- HER2 status (%) Positive (100%) Positive (100%) Positive (100%)
Treatment characteristics
- Anti-HER2 therapy Trastuzumab (100%) Trastuzumab (100%) Trastuzumab (100%)
- Chemotherapy (%) FEC+T (100%) AC+T (100%) D+C (100%)
- Response (%) 48% 45.5% 37%
doxorubicin + cyclophosphamide + taxane=AC+T; docetaxel + capecitabine=DC; FEC+Taxol=FEC+T.
Table 2: The list of the 10 MKPs and their response against anti-HER2-treatment in affymetrix and agilent datasets 
Symbol Gene name
Affymetrix dataset (n=50) Agilent dataset (n=38)
Probe ID AUC p Value Probe ID AUC p Value
DUSP1 / MKP-1 dual specificity phosphatase 1 201041_s_at n.s. n.s. 20676 0,678 0,0323
DUSP2 / PAC1 dual specificity phosphatase 2 204794_at n.s. n.s. 26030 n.s. n.s.
DUSP4 / MKP-2 dual specificity phosphatase 4 204014_at 0,686 0,0088 23420 0,687 0,0230
DUSP5 dual specificity phosphatase 5 209457_at n.s. n.s. 8917 n.s. n.s.
DUSP6 / MKP-3 dual specificity phosphatase 6 208892_s_at 0,770 3,08E-05 24661 0,687 1,57E-02
DUSP7 / MKPX dual specificity phosphatase 7 213848_at n.s. n.s. 350 0,629 0,0841
DUSP8 dual specificity phosphatase 8 206374_at n.s. n.s. 32679 n.s. n.s.
DUSP9 / MKP-4 dual specificity phosphatase 9 205777_at n.s. n.s. 11958 n.s. n.s.
DUSP10 / MKP-5 dual specificity phosphatase 10 221563_at n.a. n.a. 450 0,638 0,0709
DUSP16 / MKP-7 dual specificity phosphatase 16 208891_at 0,7667 5,29E-05 14131 n.s. n.s.
HER2
v-erb-b2 erythroblastic leukemia 
viral oncogene homolog 2 216836_s_at 0,638 4,90E-02 26639 0,809 9,50E-06
DUSP4 and DUSP6 were the only candidates associated with response to trastuzumab in both cohorts. HER2 is included as 
a control gene.
months median time to death. The two best performing 
MKPs, DUSP4 and DUSP6 reached a HR of 2.05 
(confidence interval 1.18-3.55, p=0.0088) and 2.0 (1.29-
3.1, p=0.0015), respectively. Figure 1B and 1C depict the 
Kaplan-Meier curves for DUSP4 and DUSP6.
Expression of HER2 in various BC cell lines
We assessed HER2 expression by qPCR in the 
breast cancer cell lines SKBr-3, SKTR and JIMT-1. 
Known as a HER2-overexpresssing cell line, SKBr-3 and 
its trastuzumab resistant subclone, SKTR, were indeed 
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highly expressing the HER2 mRNA, and expression levels 
did not differ between parental cells and derived subclones 
(p>0.1). HER2 expression at the mRNA level in SKBr-3 
and SKTR cell lines was significantly higher compared to 
the JIMT-1 cell line (p=0.002), even though each of them 
were designated as HER2-positive.
Cell proliferation in the presence of trastuzumab
All cell lines were exposed for 72 hours to 
increasing concentrations of trastuzumab (SKBr-3: 0.125-
16 μg/mL; SKTR: 0.002-20 μg/mL; JIMT-1: 2.5-40 μg/
mL). In agreement with previous reports, growth of the 
parental SKBr-3 cell line was inhibited by trastuzumab, 
with an IC50 value of 1μg/mL (Figure 2). Trastuzumab 
did not inhibit proliferation of SKTR and JIMT1 cells 
even at the highest concentrations, corresponding 
approximately to 2 times (SKTR) or 4 times (JIMT-1) of 
the pharmacologically applicable dose (Figure 2).
RNA interference decreasing DUSP6 and DUSP4 
expression
We verified the ability of DUSP6 and DUSP4 
siRNAs to reduce the endogenous mRNA levels in 
SKTR and JIMT-1 cell lines after a 72 hour long siRNA 
treatment. The silencing efficacy compared to a negative 
siRNA transfected control in SKTR cell line were 78.3% 
for DUSP6 and 86.2% for DUSP4, and in JIMT-1 cell line 
were 72.3% for DUSP6 and 81.7% for DUSP4. Silencing 
efficacy is illustrated in Figure 3A and binding of the 
siRNA oligos in Figure 3B. siRNA treatment did not alter 
the morphology of the cells (Figure 3C).
Treatment with DUSP4 specific siRNA induces 
sensitivity to trastuzumab in SKTR and JIMT-1 
cell lines
To observe the roles of DUSP6 and DUSP4 in 
trastuzumab resistance, we combined siRNA transfection 
Figure 1: Schematic overview of the study (A) and Kaplan-Meier survival plot of the two best performing MKPs, DUSP4 (B) and DUSP6 
(C) in 252 HER2 positive patients.
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with a 10 μg/ml trastuzumab treatment, after which 
an MTT assay was performed. Viability of transfected 
SKTR and JIMT-1 cells significantly decreased after 
DUSP4 siRNA treatment compared to negative control 
siRNA transfected cells as a consequence of trastuzumab 
treatment (SKTR: p=0.016; JIMT-1: p=0.016). In contrast, 
DUSP6 siRNA transfected and trastuzumab treated cells 
did not exhibit changes in cell viability (SKTR: p>0.1; 
JIMT-1: p>0.1). Results of the trastuzumab combined 
silencing experiments are illustrated in Figure 4A.
DISCUSSION
Our goal was to identify biomarkers of resistance 
for trastuzumab treatment. HER2 overexpression affects 
growth factor induced signaling, we hypothesized 
therefore a role of the endogeneous regulators of the 
mitogen-activated protein kinase (MAPK) cascade, the 
mitogen-activated protein kinase phosphatases (MKPs). 
We applied a bottom up approach in the quest for 
biomarkers. DUSP4/MKP-2 and DUSP6/MKP-3, in silico 
identified candidate MKPs associated with survival, were 
validated in vitro in HER2-overexpressing trastuzumab-
resistant cell lines.
In mammalian cells, the MAPK signaling pathway 
is a key transducer of growth factor signaling that 
incorporates three family members: the extracellular 
signal regulated kinases (ERK), the c-Jun N-terminal 
kinases (JNK), and the p38 MAPKs. Phosphorylation of 
ERK, JNK and p38 induces transcription factors involved 
in cell growth. Moreover, depending on the signaling 
context, JNK and p38 pathways are also implicated in 
cell death (Figure 4B) [28]. MKPs, as dual-specificity 
phosphatases dephosphorylate both the phospho-threonine 
and phospho-tyrosine residues of MAPKs, and provide 
negative feedback to the MAPK pathways [29]. DUSP4 
and DUSP6 belong to different subtypes of MKPs. DUSP6 
is based in the cytoplasm and its primary substrate is 
ERK. DUSP4 is located mainly in the nucleus and can 
dephosphorylate all three MAPKs [29] (Figure 4B). 
Different spatial and temporal control of MAPKs and 
substrate specificity of MKPs may explain the impact of 
DUSP4 silencing in our study that was not associated with 
DUSP6 downregulation.
Figure 2: Trastuzumab sensitivity of resistant SKTR and JIMT-1 cell lines. Dose-response curves after 72h trastuzumab 
treatment with concentrations ranging between 0.002-20 μg/mL for SKTR and 2.5-40 μg/mL for JIMT-1 cell lines. % relative cell viability 
refers to the growth of trastuzumab treated cells relative to untreated control cells. The dashed line represents the pharmacologically 
relevant concentration of trastuzumab (10 μg/mL). The growth of parental SKBr-3 cell line was inhibited by trastuzumab, with an IC50 
value of 1μg/mL.
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DUSP4 expression has been shown to be altered 
in a variety of human cancers. Higher expression of 
DUSP4 was described in primary breast cancer [30], 
colorectal adenocarcinoma [31], pancreatic cancer [32], 
human melanoma cells [33], and as a result of chemical 
hepatocarcinogenesis in rats [34]. DUSP4 overexpression 
increased proliferation in colorectal carcinoma cell lines 
[31]. Overall and disease-free survival was associated 
with DUSP4 expression in colorectal adenocarcinoma 
[35]. In contrast, activating EGFR-mutation was related 
to downregulation of DUSP4 in lung adenocarcinomas, 
and in vitro knockdown of DUSP4 increased cell 
proliferation [36]. DUSP4 is frequently lost in early-
onset and high-grade breast carcinomas [37]. In basal-like 
breast cancers, especially in chemotherapy resistant triple 
negative breast cancer (TNBC), low DUSP4 mRNA is 
coupled with high RAS-ERK activation, that also relates 
to shorter recurrence free survival [38]. Using 230 tissue 
samples, high DUSP4 mRNA expression was observed 
in HER2-overexpressing tumors [38]. RNAi-mediated 
DUSP4 depletion decreased proliferation in mouse 
mammary tumor cells both in vitro and in vivo [37, 39]. 
DUSP4 was identified as one of the genes responsible 
for resistance against multiple chemotherapy agents 
Figure 3: Silencing efficacy after siRNA treatment. (A) Expression of DUSP4 mRNA andDUSP6 mRNAnormalized to β-actin in 
Negative control siRNA (sc-siRNA) and DUSP4 siRNA treated SKTR and JIMT-1 cells. (B) Schematic view of DUSP4 and DUSP6 genes. 
BothDUSP4 andDUSP6 possess two isoforms. The position of tested siRNAs is shown, and the location of the more effectively silencing 
from the two is marked with a bold arrow. Binding location of gene specific primers spanning both isoforms is indicated with a line arrow. 
(C) Morphology of SKTR a. untreated control cells; b. cells treated with DUSP4 siRNA; c. cell treated with Negative control siRNA.
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including methotrexate, mitoxantrone, mitomycin C and 
etoposide [40]. In human embryonic kidney cells 293 
(HEK293) overexpression of DUSP4 rescued cells from 
apoptosis when exposed to UV-C or cisplatin treatment 
by selectively dephosphorylating JNK [41]. In summary, 
DUSP4 exerts complex control on cell proliferation, and 
can play opposite role in tumorigenesis depending on 
tissue and molecular subtype.
Although high expression of both DUSP4 and 
DUSP6 is associated with worse survival (Figure 1B and 
1C), DUSP6 downregulation combined with simultaneous 
trastuzumab did not reduce cell viability. The role of 
DUSP6 as a tumor suppressor or potential oncogene is 
tissue specific. Significant reduction of DUSP6 thwarts 
negative feedback on ERK, thus increases the activation 
of ERK1/2 MAP kinase pathway. As a consequence, low 
DUSP6 expression accelerates cell growth in pancreatic 
cancer [29]. Conversely, DUSP6 expression was abrogated 
in invasive pancreatic carcinomas compared to precursor 
lesions [42]. In contrast, in a model of HER2-positive 
BC, cells activated with EGF strongly overexpressed 
DUSP6, while HER2 expression downregulated by 
a stable intracellular expression of an anti-HER2 
antibody resulted in DUSP6 downregulation. Publicly 
available HER2-positive breast cancer datasets also 
confirmed DUSP6 overexpression, suggesting a specific 
involvement of DUSP6 in breast cancer [43]. The potential 
difference in spatial and temporal control of MAPKs, 
tissue and substrate specificity of MKPs requires further 
investigations to explain the lack of impact of DUSP6 
downregulation on cell viability.
The simultaneous siRNA and trastuzumab treatment 
reduced viability in both SKTR and JIMT-1 cell lines. 
However, comparing the effectiveness of treatment 
highlights their markedly different responses to DUSP4 
siRNA-combined trastuzumab (Figure 4A). SKTR and 
JIMT-1 cell lines represent different models of HER2-
positive BC. HER2 mRNA expression was significantly 
higher in SKBr-3 and SKTR cells compared to JIMT-1, and 
similar differences have been described at the protein level 
[44]. Currently available molecular taxonomy of BC does 
not distinguish subpopulations within clinically HER2-
positive BC patients. However, trastuzumab responsiveness 
is suggested to be dependent on BC subtypes (e.g. luminal, 
basal, HER2-enriched and claudin-low) within the 
clinically HER2-positive BC population [45].
JIMT-1 was derived from a clinically trastuzumab 
resistant patient [46], and belongs to the basal subtype 
within the clinically HER2-positive breast cancer 
populations. JIMT-1 is naturally enriched with stem 
cell markers, and is distinguished from other HER2 
positive cell lines by harboring several co-existing drug 
resistance mechanisms, including activating mutation of 
the PIK3CA gene, low PTEN expression, high NRG1 
expression, and relatively low expression of HER-2 
receptor protein (despite gene amplification) [47]. In 
contrast, SKBr-3 carries the wild-type of PIK3CA and 
represents a preclinical model of HER2 gene amplified 
breast cancer that expresses high levels of EGFR [48]. 
The different response between SKTR and JIMT-1 to 
DUSP4 siRNA-combined trastuzumab supports the 
importance of subdivision of clinically HER2-positive 
BC populations. However, reversing resistance in both 
cell lines, that represent different subtypes of HER2-
positive BC by silencing a single member of the MAPK 
pathway, highlights the overarching role of DUSP4 as 
promising marker of resistance across multiple subtypes. 
The transient nature of the siRNA treatment did not allow 
Figure 4: Effects of DUSP4 and DUSP6 silencing on cell viability after trastuzumab treatment. (A) Normalized viability 
of SKTR and JIMT-1 cells treated with 10 μg/mL trastuzumab (T) after DUSP4 and DUSP6 silencing compared to Negative control siRNA 
(sc-siRNA) treated cells (mean with SEM) and (B) simplified scheme of the targets of DUSP4 and DUSP6. DUSP4 potentially promotes 
both survival and apoptosis by dephosphorylating ERK, JNK and p38.
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to study long term consequences of DUSP4 knockdown 
because the effects of RNA silencing started to diminish 
after 72 hours. To study long term effects of DUSP4 on 
proliferation would require a different methodology, such 
as a permanent gene knockdown with a shRNA contruct.
Significant improvement has been achieved in 
the treatment of HER2-positive breast cancer since 
trastuzumab became licensed in 1998. However, only 
a slice of patients enjoy the benefits of anti-HER2 
therapy, and inherent or de novo resistance poses a 
serious challenge. In our study we examined the MKP 
family as potential candidate biomarkers of resistance 
by using microarray data of trastuzumab treated patients. 
Applying in vitro gene silencing coupled with independent 
validation in clinical cohorts, we pinpointed DUSP4 as the 
most promising MKP correlated to trastuzumab resistance 
in HER2-positive breast cancer patients. Given the highly 
tissue specific role of DUSP4, strategies that target DUSP4 
could be developed and explored in this patient population.
MATERIALS AND METHODS
Trastuzumab-treated breast cancer patients
We used two different discovery cohorts of 
trastuzumab-treated breast cancer patients: one comprising 
50 patients at the MD Anderson Cancer Center by F.J.E., 
a second dataset of two studies comprising 38 patients 
published in GEO as GSE22226 and GSE22358 produced 
using Agilent arrays.
Processing of microarray data
Microarray data for the 50 patients was generated 
using Affymetrix HGU133A microarrays following 
the manufacturer’s protocols. The raw array data was 
MAS5 normalized in the R environment using the affy 
Bioconductor package [49]. For genes measured by several 
probe sets, the most reliable probe set was selected using 
JetSet [50]. Only probe sets reaching a MAS5 expression 
value of 1000 in at least one of the samples were used in 
the statistical computations. For GSE22226 and GSE42822 
we used the series matrix database containing the 
normalized gene expression data for all samples. Mapping 
between different platforms was performed by only using 
the probes measuring exactly the same sequences. For 
this, the probe sequences were downloaded from GEO 
platform database. Only probe sets having at least 20% 
standard deviation compared to the maximal value were 
investigated in the analysis (n=13, 295).
Statistical analyses
ROC analysis was performed in the R statistical 
environment (http://www.r-project.org) using the ROC 
Bioconductor library (http://www.bioconductor.org). 
Statistical significance was set at p<0.05. The two 
cohorts comprising of 50 and 38 patients were processed 
separately to avoid batch effects, and only genes resulting 
in significant correlation in each dataset were considered 
significant. Mapping between the platforms was performed 
using the annotation tables of Affymetrix (http://www.
affymetrix.com). The final ranking of the genes was 
performed by computing the average AUC across the two 
platforms.
Datasets for survival analysis
GEO (http://www.ncbi.nlm.nih.gov/geo), EGA 
(http://www.ebi.ac.uk/) and TCGA (http://cancergenome.
nih.gov/) were searched using the keywords “breast”, 
“cancer” and “survival”. All available samples were 
downloaded and processed as described above. HER2-
positivity was determined by using the expression values 
of the probe set 216836_s_at as described previously 
[51]. All together 252 HER2 positive patients with 
available relapse-free survival data were identified. In 
these, Kaplan-Meier analysis was performed as described 
previously [52].
Cell lines and culture
Breast cancer cell lines with an amplified HER2 
oncogene were chosen to model HER2-positive 
trastuzumab resistant breast carcinoma: trastuzumab 
sensitive SKBr-3, trastuzumab resistant SKTR and JIMT-
1. JIMT-1 cell lines were purchased from the American 
Type Culture Collection (Manassas, VA, USA). JIMT-
1 is an inherently trastuzumab resistant estrogen and 
progesterone negative breast carcinoma cell line from 
epithelial origin [46]. JIMT-1 cells were cultured in 
high glucose DMEM (Gibco) supplemented with 10% 
FBS, penicillin and streptomycin. Cells were housed 
at 37°C with 5% CO2. Cell lines were tested regularly 
for the presence of mycoplasma (MycoAlert™ Plus 
Mycoplasma Detection Kit, Lonza, USA) according to the 
manufacturer's recommendations.
Generation of trastuzumab resistant SKTR 
subclone
SKBr-3 (SK) breast carcinoma cells were obtained 
from Eucellbank (University of Barcelona). SKBr-3 cells 
were routinely grown in McCoy’s (Gibco) supplemented 
with 10% FBS (HyClone Laboratories), 1% L-glutamine, 
1% sodium pyruvate, 100 U/mL penicillin, and 100 μg/
mL streptomycin (Gibco). Trastuzumab-resistant SK 
cells (SKTR) were developed by exposing SK cells 
continuously to trastuzumab (Herceptin®, Hoffmann-La 
Roche Pharma), starting with 1μM concentration for three 
months of exposure and increasing the concentration up to 
2 μM for a 12 months period, as we previously described 
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[53]. Thus, cells resistant to trastuzumab were maintained 
in 2 μM trastuzumab, a concentration at which SKBr-3 
parental cells were not viable (Figure 2).
In vitro assay of trastuzumab sensitivity
The effect of trastuzumab on the growth of parental 
SKBr-3, trastuzumab resistant SKTR and JIMT1 cells was 
measured by the MTT reduction assay [54] according to 
the manufacturer’s instructions (MTT Cell Proliferation 
Kit I, Roche). Cells were seeded at a density of 104 
cells/90μL medium/well in 96 well, flat bottomed tissue 
culture plates. Following overnight adherence, zero cell 
count was taken after which different concentrations of 
trastuzumab dissolved in sterile water were introduced 
to the wells. Control cells received vehicle without 
trastuzumab. Absorbance values were measured at 595 
nm, with 690 nm as a reference in a multiplate reader 
(Thermo Scientific, Multiscan FC). Growth inhibition is 
expressed as the percentage of cell viability compared 
to untreated cells. IC50 value represents the trastuzumab 
concentration that caused 50% growth suppression. All 
measurements were done in at least six repeats.
Gene expression measured by RT-qPCR
Cells were trypsinized and total RNA was 
extracted with the RNeasy kit (QA, Qiagen, Venlo, The 
Netherlands) according to the manufacturer’s guidelines. 
1 μg of total mRNA was reverse transcribed to cDNA 
(Maxima™ First Strand cDNA Synthesis Kit, Thermo 
Scientific). The expression of DUSP4 and DUSP6 
along with HER2 was verified by LightCycler 480 DNA 
SybrGreen Master I (Roche) using Light Cycler 480 
RT-qPCR instrument (Roche), each sample measured in 
triplicates. Gene expression values were normalized to 
an internal control gene (β-actin). NCBI Blast was used 
to eliminate potential cross-hybridization (http://blast.
ncbi.nlm.nih.gov). Sequence of the used primers were: 
β-actin forward: 5’-CCCTGGAGAAGAGCTACGAG-3’, 
reverse: 3’-GAAGGAAGGCTGGAAGAGT-5’; DUSP6 
forward: 5’-GCAGTTTCTCTTGGCAGCAT-3’, reverse: 
3’-CGCACTTGGTAACCTTGTC-5’; DUSP4 forward: 
5’-TGGAAGCCATAGAGTACATCGA-3’, reverse: 
3’-CCTCACCCGTTTCTTCATCA-5’; HER2 forward: 
5’-ACCTGGAACTCACCTACCTG-3’, reverse: 
3’-ACTTGGTTGTGAGCGATGAG-5’.
Gene silencing by siRNA
We employed siRNA concentration to achieve 
the highest silencing efficacy based on a previously 
tested GAPDH positive control siRNA (Silencer Select, 
Life Technologies) [55]. For both DUSP4 and DUSP6 
two pre-designed Silencer Select siRNAs were tested 
(Silencer Select IDs DUSP4: s223450, s223451; DUSP6: 
s4379, s4380, Life Technologies), and the one with higher 
silencing efficacy was selected for subsequent drug 
combined silencing experiments. To provide a baseline 
to compare siRNA-treated samples, control cells received 
Negative Control siRNA No. 1 (Silencer Select, Life 
Technologies) that does not target any gene product. To 
perform silencing, 3x105 cells/well were plated to each 
well of a 6 well plate in duplicates for each siRNA. 
Cells were transfected by Lipofectamine RNAiMax 
(Life Technologies) transfection reagent. After 24 hours, 
culture media was renewed and cells were incubated for 
an additional 48 hours. Cells were trypsinised and RNA 
silencing efficacy was measured by RT-qPCR. Expression 
of target genes from cells treated with Silencer Select 
siRNAs was compared to Negative Control siRNA 
transfected cells.
RNA interference combined with trastuzumab 
treatment
To assess the role of selected candidate genes in 
trastuzumab resistance, we combined siRNA transfection 
with drug treatment on a 96 well plate. In each well, 104 
cells /90μL were plated out and transfected with 30 nm 
siRNA in six repeats. After overnight incubation, cell count 
was taken and 10 μg/ml/well trastuzumab was introduced, 
that also corresponds to the pharmacologically relevant 
concentration [56]. Control wells received 10 μL vehicle. 
After a 48 h drug treatment, MTT assay was performed 
and absorbance values were measured. The difference in 
viability between Negative control siRNA and target-gene 
transfected cells was calculated by Kruskall-Wallis test. 
Significance level was set at p < 0.05. A summary of the 
performed analysis steps is provided in Figure 1A.
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